Tremelimumab - MedImmune

Drug Profile

Tremelimumab - MedImmune

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AIO Studien gGmbH; Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Charite - Universitatsmedizin Berlin; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer; Seoul National University Hospital; UNICANCER; University College London; University of Maryland Greenbaum Cancer Center; Yonsei University College of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Urogenital cancer
  • Phase I/II Colorectal cancer; Malignant melanoma; Oesophageal cancer
  • Phase I Cervical cancer; Diffuse large B cell lymphoma; Gynaecological cancer; Thyroid cancer; Vulvovaginal cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 01 Oct 2018 AstraZeneca plans a phase III trial for Urothelial cancer (Metastatic disease, Late-stage disease, Combination therapy) in USA, Australia, Brazil, Bulgaria, Canada, Czech Republic, Hungary, Japan, South Korea, Philippines, Poland, Turkey and Vietnam (NCT03682068)
  • 25 Aug 2018 AstraZeneca terminates a phase III trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Inresectable, Recurrent) in Japan (NCT03430466) (UMIN000026050)
  • 20 Aug 2018 Sidney Kimmel Comprehensive Cancer Center plans a phase II trial for Hepatocellular carcinoma (First line therapy) in USA (NCT03638141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top